Literature DB >> 21069865

Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.

Giuseppe Visani, Massimo Breccia, Antonella Gozzini, Giorgina Specchia, Enrico Montefusco, Enrica Morra, Mario Annunziata, Andrea Camera, Francesco Cavazzini, Fabio Stagno, Patrizia Pregno, Emilio Usala, Valeria Santini, Pier Paolo Piccaluga, Alessandro Isidori.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21069865     DOI： 10.1002/ajh.21871

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  3 in total

1.  The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply).

Authors:  Giuseppe Visani; Massimo Breccia; Enrico Montefusco; Enrica Morra; Valeria Santini; Alessandro Isidori
Journal:  Haematologica       Date:  2011-04       Impact factor: 9.941

2.  Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).

Authors:  Henrik Hjorth-Hansen; Leif Stenke; Stina Söderlund; Arta Dreimane; Hans Ehrencrona; Tobias Gedde-Dahl; Bjørn Tore Gjertsen; Martin Höglund; Perttu Koskenvesa; Kourosh Lotfi; Waleed Majeed; Berit Markevärn; Lotta Ohm; Ulla Olsson-Strömberg; Kari Remes; Merja Suominen; Bengt Simonsson; Kimmo Porkka; Satu Mustjoki; Johan Richter
Journal:  Eur J Haematol       Date:  2014-09-13       Impact factor: 2.997

Review 3.  What Is the Optimal Dose and Schedule for Dasatinib in Chronic Myeloid Leukemia: Two Case Reports and Review of the Literature.

Authors:  Caroline Jamison; Debra Nelson; Mete Eren; Dron Gauchan; Ryan Ramaekers; Max Norvell; Mehmet Sitki Copur
Journal:  Oncol Res       Date:  2016-01-21       Impact factor: 5.574
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.